Memorial Sloan-Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

Researchers at Memorial Sloan-Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

When new cancer drugs are shown to be largely ineffective, exceptional cases of good outcome may pave the way for new treatments that could benefit a smaller group of patients.

In the future, more-advanced genetic testing might offer better ways to match up patients who need a bone marrow transplant with potential donors.

Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.

Memorial Sloan-Kettering investigators hope their new web tool will improve the accessibility of large-scale genome-sequencing information for cancer researchers everywhere, and accelerate research and therapeutic discovery.